U.S. Aquaculture Vaccines Market Size & Outlook, 2023-2030
U.S. aquaculture vaccines market, 2018-2030 (US$M)
Related Markets
U.S. aquaculture vaccines market highlights
- The U.S. aquaculture vaccines market generated a revenue of USD 62.4 million in 2023 and is expected to reach USD 109.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
- In terms of segment, inactivated (killed) was the largest revenue generating vaccine type in 2023.
- Other Vaccines is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Aquaculture vaccines market data book summary
| Market revenue in 2023 | USD 62.4 million |
| Market revenue in 2030 | USD 109.5 million |
| Growth rate | 8.4% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated (killed) |
| Fastest growing segment | Other Vaccines |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Modified/ Attenuated Live, Inactivated (Killed), Other Vaccines |
| Key market players worldwide | Zoetis, Phibro Animal Health Corp Class A, Elanco Animal Health Inc, Merck & Co Inc, Choong Ang Vaccine Laboratories (CAVAC), Kyoto Biken Laboratories, Nissenken, KBNP, Vaxxinova, HIPRA |
Other key industry trends
- In terms of revenue, U.S. accounted for 15.7% of the global aquaculture vaccines market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. aquaculture vaccines market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 109.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Aquaculture Vaccines Market Scope
Aquaculture Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. aquaculture vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to aquaculture vaccines market will help companies and investors design strategic landscapes.
Inactivated (killed) was the largest segment with a revenue share of 34.62% in 2023. Horizon Databook has segmented the U.S. aquaculture vaccines market based on modified/ attenuated live, inactivated (killed), other vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Most of the commercially available vaccines in the U.S. have been developed for use in salmonids. These target various diseases such as furunculosis, vibriosis, bacterial kidney disease, Infectious Salmon Anemia (ISA), cold water vibriosis, enteric redmouth disease, and others, either separately or in combination.
In case a USDA-licensed vaccine is unavailable, autogenous vaccines offer an effective solution for protecting fish health. Elanco, Pharmaq (Zoetis), and Merck are major global players and also dominate the U.S. Aquaculture Vaccines market.
Merck Animal Health for instance, develops and markets vaccines under the brands Aquavac and Norvax. Its line of Aquavac and Norvax vaccines are intended for aquaculture species such as Atlantic salmon, tilapia, rainbow trout, and European sea bass.
Reasons to subscribe to U.S. aquaculture vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. aquaculture vaccines market databook
-
Our clientele includes a mix of aquaculture vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. aquaculture vaccines market , including forecasts for subscribers. This country databook contains high-level insights into U.S. aquaculture vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. aquaculture vaccines market size, by vaccine type, 2018-2030 (US$M)
U.S. Aquaculture Vaccines Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
